Literature DB >> 21734420

Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation.

Kaoru Tsuchiya1, Mina Komuta, Yutaka Yasui, Nobuharu Tamaki, Takanori Hosokawa, Ken Ueda, Teiji Kuzuya, Jun Itakura, Hiroyuki Nakanishi, Yuka Takahashi, Masayuki Kurosaki, Yasuhiro Asahina, Nobuyuki Enomoto, Michiie Sakamoto, Namiki Izumi.   

Abstract

OBJECTIVE: Keratin (K) 19 positivity has been reported to be a useful predictive marker for recurrence in patients with hepatocellular carcinoma (HCC) who have undergone hepatic resection. We investigated the clinical usefulness of K19 positivity in patients who had received curative radiofrequency ablation (RFA).
METHODS: We retrospectively evaluated the clinicopathological features, including imaging and K19 expression, in 246 patients with HCC who were within the Milan criteria and had received curative RFA. Using a two-step insertion method, tumor biopsies were obtained just prior to RFA and were evaluated histologically.
RESULTS: Tumor seeding due to liver biopsy and RFA was not observed. Ten patients (4.1%) had K19-positive HCC. Imaging findings were similar between K19-positive and -negative HCC (p = 0.187). Nine out of 10 patients (90%) who had K19-positive HCC had recurrence of HCC after RFA, and intrahepatic recurrences were observed within 12 months in 6 out of 10 (60.0%). K19 positivity was a significant risk factor for recurrence (p < 0.0001) and early recurrence (<1 year after RFA; p =0.012). K19 expression (p = 0.016) was an independent risk factor for tumor status exceeding the Milan criteria after RFA.
CONCLUSION: Expression of K19 is related to high recurrence of HCC after curative RFA.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734420     DOI: 10.1159/000328448

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  20 in total

Review 1.  Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma.

Authors:  Nathalie Ganne-Carrié; Jean-Charles Nault; Marianne Ziol; Gisèle N'Kontchou; Pierre Nahon; Véronique Grando; Valérie Bourcier; Sandrine Barge; Michel Beaugrand; Jean-Claude Trinchet; Olivier Seror
Journal:  Hepat Oncol       Date:  2014-12-11

Review 2.  Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress.

Authors:  Elizabeth M Brunt; Valerie Paradis; Christine Sempoux; Neil D Theise
Journal:  Hepat Oncol       Date:  2015-07-28

Review 3.  Radiomics of hepatocellular carcinoma.

Authors:  Sara Lewis; Stefanie Hectors; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2021-01

Review 4.  Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression.

Authors:  Hyungjin Rhee; Haeryoung Kim; Young Nyun Park
Journal:  Liver Cancer       Date:  2020-10-23       Impact factor: 11.740

5.  Expression of K19 and K7 in dysplastic nodules and hepatocellular carcinoma.

Authors:  Jun Sang Bae; Ha Na Choi; Sang Jae Noh; Byung Hyun Park; Kyu Yun Jang; Cheol Keun Park; Woo Sung Moon
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

6.  Human lung cancer-derived microparticles enhanced angiogenesis and growth of hepatoma cells in rodent lung parenchyma.

Authors:  Sheung-Fat Ko; Shu-Yuan Hsu; Chih-Hung Chen; Pei-Hsun Sung; Meng-Shen TongYen-Yi Zhen; Yi-Ling Chen; Tien-Hung Huang; Sheng-Yi Chen; Gour-Shenq Kao; Hong-Hwa Chen; Chia-Lo Chang; Cheuk-Kwan Sun; Hsueh-Wen Chang; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

Review 7.  Prognostic factors for hepatocellular carcinoma recurrence.

Authors:  Antonio Colecchia; Ramona Schiumerini; Alessandro Cucchetti; Matteo Cescon; Martina Taddia; Giovanni Marasco; Davide Festi
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

8.  Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry.

Authors:  Hong Mu; Kai-Xuan Lin; Hong Zhao; Shu Xing; Cong Li; Fang Liu; Hai-Zhen Lu; Ze Zhang; Yu-Lin Sun; Xi-Yun Yan; Jian-Qiang Cai; Xiao-Hang Zhao
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

Review 9.  Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy.

Authors:  Yuan-Mao Lin; Ryosuke Taiji; Marco Calandri; Bruno C Odisio
Journal:  Curr Oncol Rep       Date:  2021-04-15       Impact factor: 5.075

Review 10.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

Authors:  Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-28       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.